# Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

> **NCT01313884** · PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 3 (actual)

## Conditions studied

- Bone Cancer
- Ewing's Sarcoma

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Vincristine
- **DRUG:** Temozolomide
- **DRUG:** Doxorubicin
- **DRUG:** Cytoxan
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT01313884
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study did not reach primary objective; study did not accrue enough patients.
- **Last updated:** 2017-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313884, "Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01313884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*